nextcure.com (NXTC): Rasio rega marang prakiraan pendapatan
Will the reputable management of NextCure, Inc. (NXTC) ensure business success? Revenue growth is projected through the market launch of NC318 antibodies, which is supported by the forward price-to-sales ratio, currently standing at . However, fierce competition for capital and the risk of more efficient gene-editing methods emerging present serious challenges for the company.
Rincian analitis perusahaan NextCure Corporation (NXTC)
- rega saham lan target rega konsensus:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- indikator total utang lan likuiditas perusahaan:
Rasio Total Utang marang Ekuitas NextCure, Inc.|NXTC - Rasio silihan jangka dawa marang modal|Utang jangka cendhak marang modal NextCure, Inc.|NXTC - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku NextCure Corporation|NXTC - Utang jangka dawa|Utang jangka cendhak perusahaan NextCure|Rasio cepet nextcure.com
- data bathi bisnis lan rasio investasi:
NXTC - Bathi resik|Bathi sing dikarepake NextCure, Inc.|NXTC - Kapitalisasi marang bathi resik|Prakiraan rega marang bathi NextCure Corp|NXTC - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan NextCure Corporation|NXTC - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) NextCure|NXTC - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan nextcure.com|NXTC - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep NextCure, Inc.
- rincian pendapatan lan dodolan:
Ringkesan analisis perusahaan:NextCure NXTC
To find a balance between valuation and business quality, use the ratio of market capitalization to projected revenue, which measures the premium paid for future success. Since NextCure, Inc. (NXTC) has no commercial products pending FDA approval, the forward P/S trend allows for an assessment of how current market expectations align with drug development potential and the effectiveness of the company's cost management.
Analisis pesaing
ImmunityBio - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Immunocore Holdings IMCR|JANX - Rasio rega marang prakiraan pendapatan|RCUS (Arcus Corp) - Kapitalisasi marang prakiraan pendapatan|Zymeworks Inc. (ZYME) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep tangotx.com (TNGX)|Multiplikator forward rega marang pendapatan IOVA|IMTX - Prakiraan rega marang pendapatan|Multiplikator forward rega marang pendapatan XNCR (Xencor Corp)|Rasio rega marang pendapatan sing dikarepake CMPX|Multiplikator Forward P/S REPL (Replimune Group, Inc.)|Rega forward marang dodolan LYEL|Innate Pharma - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Pyxis Oncology, Inc.|cgen.com (CGEN) - Rasio rega marang prakiraan pendapatan|IO Biotech Inc. - Rega forward marang dodolan|STRO (Sutro Biopharma, Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S minktherapeutics.com|Rasio rega marang prakiraan pendapatan Werewolf Therapeutics (HOWL)|IMMX: Rega mangsa ngarep marang pendapatan|ALX Oncology Holdings - Multiplikator forward rega marang pendapatan|cuebiopharma.com (CUE) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|PDSB - Rasio rega marang prakiraan pendapatan|SONN (Sonnet BioTherapeutics) - Kapitalisasi marang prakiraan pendapatan|MAIA: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Liminatus Pharma Inc. (LIMN)|Multiplikator forward rega marang pendapatan LVTX|Kapitalisasi marang prakiraan pendapatan LPTX (Leap Tx)|Multiplikator forward rega marang pendapatan INTS (Intensity Therapeutics)|Rasio rega marang pendapatan sing dikarepake SNSE|Multiplikator Forward P/S TOVX (Theriva Biologics)|GRTS - Multiplikator forward rega marang pendapatan|KA: Multiplikator forward rega marang pendapatan|NEXI - Multiplikator Forward P/S|turnstonebio.com (TSBX) - Rasio rega marang prakiraan pendapatan|vaccinex.com - Rega forward marang dodolan|HARP (Harpoon Therapeutics, Inc.) - Multiplikator Forward P/S
